Cookie Consent by Free Privacy Policy Generator
News
05 October 2022
EU
Allergy
INFORM, CARE

immuniverse meeting june 2022

On 13-14th June, EFA attended the annual meeting of ImmUniverse, an Innovative Medicines Initiative (IMI) research funded project aiming at improving diagnostic and therapeutic options for patients living with immune-mediated inflammatory diseases, including atopic eczema and ulcerative colitis. In ImmUniverse, EFA brings the perspective and voice of atopic eczema patients.

Celebrated at Humanitas University in Milan, the first in-person gathering of the Immuniverse partners since its launch in February 2020.

One key update was the project’s second periodic report being accepted by the Innovative Health Initiative (IHI) just prior the meeting. This presented the perfect occasion to discuss the feedback received and to align on the next steps.

EFA, who coordinates the Patients Input Platform together with the European Federation of Crohn's & Ulcerative Colitis Associations (EFCAA) and the European Patients’ Forum (EPF), brought to the table the patients’ perspective by providing the patients feedback on the work done so far and inviting all the consortium members to continue involving the patients in all the steps of the research. Involving patients is crucial to ensure that the results of the study meet the patients need and have an impact on the quality of life of atopic eczema and ulcerative colitis patients.

Overall, it was a fruitful and lively meeting. It was invigorating to meet the partners face-to-face after adjusting to online meetings and way of working under the COVID-19 pandemic. The meeting offered a great opportunity to share updates on the project progress, explore its challenges and the tasks ahead with the project partners. The consortium and EFA looks forward to more in person meetings in the next months and years of the project.

Check ImmUniverse website for more information on the project, its advances and news.